Lung cancer remains the leading cause of cancer-related deaths worldwide, owing to its late detection and aggressive nature. The disease is categorised mainly into two types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). While traditional treatments such as surgery, chemotherapy, and radiation therapy have been the mainstay for lung cancer management, the advent of immunotherapy has brought a new dimension to treatment strategies.

Understanding Lung Cancer
Symptoms and Diagnosis of Lung Cancer
Treatment Options for Lung Cancer
Mechanisms of Action
Efficacy and Challenges
Myths & Facts about Lung Cancer Immunotherapy
Did You Know?
Conclusion
Whom to Consult
Frequently Asked Questions

Understanding Lung Cancer

Lung cancer occurs when abnormal cells in the lungs grow uncontrollably, resulting in tumours. Risk factors include smoking, exposure to second-hand smoke, air pollution, and genetic predispositions. The two primary types of lung cancer are:

Non-Small Cell Lung Cancer (NSCLC): This accounts for approximately 85% of lung cancer cases and is further divided into subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
Small Cell Lung Cancer (SCLC): This type is less common but more aggressive and is often associated with smoking.

Symptoms and Diagnosis of Lung Cancer

Symptoms of Lung Cancer:

Lung cancer symptoms can vary significantly among individuals, but common signs include:

Persistent Cough: A cough that does not go away or worsens over time is often one of the first noticeable symptoms.
Coughing Up Blood: Haemoptysis, or coughing up blood, can occur even in small amounts and is a concerning sign.
Chest Pain: Discomfort or pain in the chest, which may worsen with deep breaths or coughing.
Shortness of Breath: Difficulty breathing, or persistent wheezing can indicate lung obstruction.
Fatigue: A general sense of exhaustion or weakness that does not improve with rest.
Weight Loss: Unexplained weight loss and loss of appetite are common in advanced stages.
Recurrent Infections: Frequent respiratory infections such as bronchitis or pneumonia may occur.

Less common symptoms can include:

Hoarseness: Changes in voice quality due to tumour effects on surrounding structures.
Difficulty Swallowing: This may arise if the tumour presses on the oesophagus.
Clubbing: Changes in the appearance of fingers and toes, characterised by enlarged tips.

These symptoms often develop as the cancer progresses, making early diagnosis challenging.

Diagnosis of Lung Cancer:

Diagnosing lung cancer typically involves a combination of medical history review, physical examination, and a series of diagnostic tests:

Medical History and Physical Examination: Healthcare providers will enquire about symptoms, smoking history, and exposure to risk factors. They may listen for abnormal sounds in lungs.

Imaging Tests:

Chest X-ray: Often the first imaging test performed; it can reveal masses or abnormalities.
CT scan: Provides detailed images of the lungs and can help identify tumours and their size.

Biopsy Procedures: If lung cancer is suspected based on imaging results, a biopsy is necessary to confirm diagnosis:

Bronchoscopy: Involves inserting a thin tube through the nose or mouth into the lungs to collect tissue samples.
Needle Biopsy: A needle is guided by imaging techniques to extract tissue from a lung mass.

Additional Tests:

Sputum Cytology: Examining mucus coughed up from the lungs for cancer cells.
PET Scan: Helps determine if cancer has spread to other parts of the body.
Staging: If diagnosed, further tests will assess how far the cancer has spread (staging), which is critical for determining treatment options.

Treatment Options for Lung Cancer

Treatment plans for lung cancer vary based on the type and stage of the disease. Common approaches include:

Surgery: Removal of tumours or affected lung tissue.
Chemotherapy: Use of drugs to kill cancer cells.
Radiation Therapy: Targeted radiation to shrink tumours.
Targeted Therapy: Drugs that target specific genetic mutations in cancer cells.

Immunotherapy for Lung Cancer

Immunotherapy in Lung Cancer

Immunotherapy represents a significant breakthrough in lung cancer treatment, particularly for NSCLC. It leverages the body's immune system to recognise and attack cancer cells more effectively. Unlike traditional therapies that indiscriminately target both healthy and malignant cells, immunotherapy aims to enhance the immune response specifically against cancerous cells.

Mechanisms of Action

Immunotherapy employs several strategies:

Immune Checkpoint Inhibitors: These drugs block proteins that prevent immune cells from attacking cancer. Key inhibitors include:
PD-1/PD-L1 inhibitors: These prevent cancer cells from evading immune detection by blocking the interaction between PD-1 on T-cells and PD-L1 on tumour cells.
CTLA-4 inhibitors: These enhance T-cell activation against tumours.
Therapeutic Vaccines: Designed to stimulate an immune response against specific antigens present on tumour cells.
Monoclonal Antibodies: These are engineered antibodies that can target specific proteins on cancer cells.

Efficacy and Challenges

Clinical trials have demonstrated that immunotherapy can lead to significant improvements in survival rates for patients with advanced NSCLC. For instance, drugs like pembrolizumab and nivolumab have shown durable responses in many patients. However, challenges remain:

Not all patients respond to immunotherapy; identifying predictive biomarkers like PD-L1 expression is crucial.
Resistance mechanisms can develop, limiting the effectiveness of treatment over time.
Recent advancements are focusing on combining immunotherapy with other treatments like chemotherapy or targeted therapies to enhance efficacy and overcome resistance.

Myths & Facts about Lung Cancer Immunotherapy

Myth 1: Immunotherapy works for all lung cancer patients.
Fact: While immunotherapy has shown remarkable results in some patients, it's not effective for everyone. Response rates vary, and ongoing research aims to identify predictive factors for better patient selection.

Myth 2: Immunotherapy has no side effects.
Fact: Although generally better tolerated than chemotherapy, immunotherapy can cause side effects such as fatigue, skin reactions, and in rare cases, autoimmune-like conditions.

Myth 3: Immunotherapy is only used as a last resort.
Fact: In some cases, immunotherapy is now used as a first-line treatment for certain types of lung cancer, especially when specific biomarkers are present.

Myth 4: Once you start immunotherapy, you can't switch to other treatments.
Fact: Patients who don't respond to immunotherapy or develop resistance can often still benefit from other treatment modalities.

Myth 5: Immunotherapy cures lung cancer.
Fact: While immunotherapy has led to long-term remission in some patients, it's not a cure for all. It's a powerful tool in managing lung cancer, potentially turning it into a chronic condition for some.

Did You Know?

Immunotherapy can potentially turn lung cancer into a chronic, manageable disease for some patients, significantly improving their quality of life and survival rates.
The first immunotherapy drug for lung cancer was approved by the FDA in 2015, marking a pivotal moment in the fight against this devastating disease.

Conclusion

Immunotherapy for lung cancer represents a paradigm shift in oncology, offering new hope to patients who previously had limited options. As research progresses, the integration of immunotherapy with other treatment modalities promises to reshape the landscape of lung cancer management, potentially transforming this once-dreaded diagnosis into a more manageable condition.

Whom to Consult

Looking for expert advice on lung cancer treatment? Schedule a consultation today with our specialised oncologists at Narayana Health, who will work with you to develop a comprehensive and personalised care plan.

Don’t wait--- Call us today @ 08068617735

Frequently Asked Questions

Q. How is immunotherapy administered for lung cancer?
A. Immunotherapy is usually given through an intravenous (IV) infusion in a hospital or clinic setting, often every 2 to 4 weeks, depending on the treatment plan.

Q. Can immunotherapy be combined with other treatments for lung cancer?
A. Yes, immunotherapy is often combined with chemotherapy, radiation, or targeted therapies to enhance effectiveness in treating lung cancer.

Q. How long does immunotherapy treatment last for lung cancer?
A. Treatment duration varies by individual response, but many patients receive immunotherapy for up to 2 years or until the cancer shows signs of progression.

Q. Is immunotherapy suitable for small cell lung cancer (SCLC)?
A. Immunotherapy is primarily used for non-small cell lung cancer (NSCLC), but it has also shown potential in treating certain cases of small cell lung cancer.

Q. What factors influence the success of immunotherapy in lung cancer patients?
A. Success depends on factors such as the presence of specific biomarkers like PD-L1, the cancer’s stage, and the overall health of the patient’s immune system.

Table of Contents